Biohaven surges as genetic disease drug meets main study goal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Leerink Partners
September 24, 2024 9:45 AM EDTLeerink Partners analyst Marc Goodman raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $60.00 (from $55.00) while maintaining a Outperform rating.
The analyst comments "The top-line readout this morning confirmed our view that the opportunity of troriluzole in spinal cerebellar ataxia (SCA) is... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $62 at BofA Securities
September 24, 2024 6:21 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $62.00 (from $52.00) while maintaining a Buy rating.
The analyst comments "We increase our BHVN PO to $62/shr post positive pivotal data for troriluzole in spinocerebellar ataxia. While troriluzole... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at RBC Capital
September 24, 2024 6:14 AM EDTRBC Capital analyst Leonid Timashev raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $59.00) while maintaining a Outperform rating.
The analyst comments "This morning, we had a chance to catch up with mgmt after BHVN presented the topline data from their... More
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN), PT $59
September 23, 2024 12:17 PM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $59.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).
The analyst comments "Possibly an approvable package with an agreement for a post-approval study but the FDA will need to be convinced each patient was what they were labeled. The P3 program for Troriluzole is SCA has always been plagued by the fact that the control group for an aggressive disease didn't decline over the 48 weeks of the blinded trial. As a result, the treatment effect measured from a treatment arm, that also didn't decline, was not... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Baird
September 23, 2024 12:17 PM EDTBaird analyst Brian Skorney raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $60.00 (from $58.00) while maintaining a Outperform rating.
The analyst comments "Incrementally positive on new data. We remain bullish on BHVN for a multitude of reasons, but following this morning's... More
